News
Thioridazine, successfully kills cancer stem cells in the human
A team of scientists at McMaster University has discovered a drug, thioridazine, successfully kills cancer stem cells in the human while avoiding the toxic side-effects of conventional cancer treatments. "The unusual aspect of our...
News
Innovative public-private collaboration launches to tackle antibiotic research
GlaxoSmithKline and AstraZeneca welcomed the launch of a pioneering approach to antibiotic research in Europe that will see pharmaceutical and biotechnology companies working alongside public partners to tackle the rising threat from antibiotic resistance and address some of the...
News
Bayer’s Regorafenib submitted for EU and US marketing authorization
Bayer HealthCare has submitted a Marketing Authorization Application to the European Medicines Agency and a New Drug Application to the U.S. Food and Drug Administration for the oral multi-kinase inhibitor regorafenib for the treatment of patients with metastatic...
News
One million signatures needed to call upon World Health Organisation
The 1 Mission 1 Million - Getting to the Heart of Stroke initiative is launching a petition to call upon the World Health Organisation, its member states and health authorities worldwide to recognise atrial fibrillation as a risk...
News
Biomarker predicts response to cancer treatment
VIB researcher Diether Lambrechts, associated with KU Leuven, has discovered a biomarker that might potentially predict which patients will benefit more from treatment with bevacizumab (Avastin). If validated, this discovery could be an important step towards personalized medicine...
News
FDA approves generic versions of blood thinner Plavix
The U.S. Food and Drug Administration approved generic versions of the blood thinning drug Plavix, which helps reduce the risk of heart attack and stroke by making it less likely that platelets in the blood will clump and...
News
Amgen’s BiTE® antibody blinatumomab achieved high rate of complete response
Amgen announced updated results from a Phase 2 study that showed treatment with blinatumomab (AMG 103) helped achieve a high-rate of complete response (CR) in 72 percent of adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.